| Role of the p53-homologue p73 in E2F1-induced apoptosis T Stiewe, BM Pützer Nature genetics 26 (4), 464-469, 2000 | 459 | 2000 |
| The p53 family in differentiation and tumorigenesis T Stiewe Nature Reviews Cancer 7 (3), 165-167, 2007 | 408 | 2007 |
| The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes M Luu, S Pautz, V Kohl, R Singh, R Romero, S Lucas, J Hofmann, ... Nature communications 10 (1), 760, 2019 | 319 | 2019 |
| Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis T Stiewe, CC Theseling, BM Putzer Journal of Biological Chemistry 277 (16), 14177-14185, 2002 | 265 | 2002 |
| Transactivation-deficient δTA-p73 acts as an oncogene T Stiewe, S Zimmermann, A Frilling, H Esche, BM Pützer Cancer research 62 (13), 3598-3602, 2002 | 251 | 2002 |
| The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic E Kadosh, I Snir-Alkalay, A Venkatachalam, S May, A Lasry, E Elyada, ... Nature 586 (7827), 133-138, 2020 | 244 | 2020 |
| Gene expression changes in response to E2F1 activation J Stanelle, T Stiewe, CC Theseling, M Peter, BM Pützer Nucleic acids research 30 (8), 1859-1867, 2002 | 243 | 2002 |
| A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism A Pribluda, E Elyada, Z Wiener, H Hamza, RE Goldstein, M Biton, ... Cancer cell 24 (2), 242-256, 2013 | 235 | 2013 |
| Role of p73 in malignancy: tumor suppressor or oncogene? T Stiewe, BM Pützer Cell Death & Differentiation 9 (3), 237-245, 2002 | 204 | 2002 |
| Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells M Michaelis, F Rothweiler, S Barth, J Cinatl, M Van Rikxoort, ... Cell death & disease 2 (12), e243-e243, 2011 | 184 | 2011 |
| Immune and inflammatory cell composition of human lung cancer stroma GA Banat, A Tretyn, SS Pullamsetti, J Wilhelm, A Weigert, C Olesch, ... PLOS one 10 (9), e0139073, 2015 | 166 | 2015 |
| p53 family members in myogenic differentiation and rhabdomyosarcoma development H Cam, H Griesmann, M Beitzinger, L Hofmann, R Beinoraviciute-Kellner, ... Cancer cell 10 (4), 281-293, 2006 | 143 | 2006 |
| Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer P Sarode, X Zheng, GA Giotopoulou, A Weigert, C Kuenne, S Guenther, ... Science advances 6 (23), eaaz6105, 2020 | 131 | 2020 |
| Quantitative TP73 Transcript Analysis in Hepatocellular Carcinomas T Stiewe, S Tuve, M Peter, A Tannapfel, AH Elmaagacli, BM Pützer Clinical cancer research 10 (2), 626-633, 2004 | 124 | 2004 |
| DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis K Schlereth, R Beinoraviciute-Kellner, MK Zeitlinger, AC Bretz, M Sauer, ... Molecular cell 38 (3), 356-368, 2010 | 123 | 2010 |
| MGA, L3MBTL2 and E2F6 determine genomic binding of the non-canonical Polycomb repressive complex PRC1. 6 B Stielow, F Finkernagel, T Stiewe, A Nist, G Suske PLoS genetics 14 (1), e1007193, 2018 | 110 | 2018 |
| Antithetical NFAT c1–Sox2 and p53–miR200 signaling networks govern pancreatic cancer cell plasticity SK Singh, NM Chen, E Hessmann, J Siveke, M Lahmann, G Singh, ... The EMBO journal 34 (4), 517-530, 2015 | 110 | 2015 |
| Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5 F Vogiatzi, DT Brandt, J Schneikert, J Fuchs, K Grikscheit, M Wanzel, ... Proceedings of the National Academy of Sciences 113 (52), E8433-E8442, 2016 | 107 | 2016 |
| mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability N Gremke, P Polo, A Dort, J Schneikert, S Elmshäuser, C Brehm, ... Nature communications 11 (1), 4684, 2020 | 105 | 2020 |
| How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance T Stiewe, TE Haran Drug Resistance Updates 38, 27-43, 2018 | 104 | 2018 |
